Teva Pharmaceutical Industries Generics Company Intelligence Report

Date: January 22, 2011
Pages: 54
US$ 340.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Teva Pharmaceutical Industries Generics Company Intelligence Report
Teva is the largest generic pharmaceutical manufacturer in the world, with sales worth US$13.9 billion in 2009. The company is Israeli-owned and headquartered, although around 62% of revenues are gained in the USA.

In July 2005, Teva announced a merger with IVAX, one of the USA’s leading generic companies. The acquisition was completed in January 2006, in a deal worth some US$7.4 billion. The deal strengthened Teva’s position in the USA and Latin America.

In 2008, Teva announced it was acquiring the US generic firm, Bentley Pharmaceuticals, in a deal worth some US$360 million. Although based in the US, Bentley’s main business was in Spain, with additional operations in other parts of Europe.

In July 2008, Teva Pharmaceutical Industries announced plans to acquire Barr in a deal worth some US$7.46 billion. The deal completed in December 2008, creating a company that operates in over 60 countries and employs some 37,000 people. The acquisition drove Teva's North America revenues increase in 2009.

While the bulk of Teva’s revenues are derived from generics, the company has one major innovative product, Copaxone. This is a treatment for multiple sclerosis. Sales of Copaxone broke the US$1 billion mark in 2005, and were worth US$2.83 billion in 2009. A second innovative product, Azilect (rasagiline, Parkinson’s disease), was launched in 2006. Teva is also involved in research in other areas such as drug delivery and biosimilars.

In February 2010, the FDA accepted for filing Teva's Biologics Licence Application for XM02, the firm's G-CSF product. Teva submitted its BLA in November 2009, underscoring the firm's scepticism that Congress would be able to create a regulatory pathway for biosimilars.

In March 2010, Teva announced that it was to acquire ratiopharm for an enterprise value of 3.625 billion euros (US$4.9 billion). The deal will position Teva as the leading generics player in Europe, and cement its position as the largest generics firm in the world. The acquisition completed on 10th August 2010.



Strategic review
Teva outlines respiratory business growth strategy

Teva Pharmaceutical Industries: main pharmaceutical manufacturing facilities
Generic products
North America
Branded products
Peptimmune files glatiramer Citizen Petition
Biopharmaceuticals and biosimilars
Teva updates status of G-CSF BLA
Teva plans further study with rituximab biosimilar
Teva ANDA Approvals January 2002 – September 2010
Barr Laboratories ANDA Approvals, January 2008 – September 2010
Pliva, Pliva Hrvatska and Pliva Lachema ANDA Approvals, January 2002 – September 2010
Recent product approvals
Lamivudine / zidovudine (EU)
Docetaxel (EU)
Lansoprazole (US)
Dorzolamide / timolol ophthalmic solution (UK)
Venlafaxine (US)
Clopidogrel (EU)
Anastrozole (US)
Ibandronic acid (EU)
Valacyclovir (US)
Adapalene (US)
Teva launches new generic oral contraceptive (US)
Atorvastatin (Canada)
Cinacalcet (US, tentative)
Tamsulosin (US)
Losartan (US)
Temozolomide (UK)
Argatroban injection (US, tentative)
Losartan (UK)
CHMP accepts safety of clopidogrel generics
CHMP update includes selected drugs for musculoskeletal and genetic diseases
Lercanidipine (UK)
Dorzolamide eye drops (UK)
Letrozole (US, tentative)
Levodopa / benserazide (UK)
Atomoxetine (US, tentative)
CHMP adopts positive opinion on Temodal generics
Filgrastim (UK)
Fexofenadine (US)
Ethinyloestradiol, norgestimate


Latest Quarterly Results, Q310
Teva Pharmaceutical Industries: quarterly results, in US$ millions
Latest Fiscal Year Results, 2009
Teva Pharmaceutical Industries: fiscal year results, in US$ millions
North America
Teva Pharmaceutical Industries: sales by geographical areas, in US$ millions
Global Branded PRODUCTS

Biogenerics and biopharmaceuticals
Teva Pharmaceutical Industries: sales by product line, in US$ millions


Teva opens a new pharmaceutical packaging plant in Hungary
Teva invests in Ontario
Mergers, acquisitions and agreements
Teva to acquire Théramex to expand global women's health business
Teva acquires ratiopharm
Teva invests additional US$11.9 million in Andromeda
Teva-KOWA Pharma to acquire majority interest in Taisho Pharmaceutical Industries
Codexis expands collaboration with Teva
Abbott and Fournier enter fenofibrate licence agreement with Teva
Vical grants Teva sales and marketing rights for Allovectin-7 in Israel
Antares receives payment from Teva for commercial development of Vibex product
Eli Lilly gains pemetrexed patent victory
Merck claims temozolomide patent lawsuit victory
Watson confirms rasagiline patent challenge
Nycomed and Pfizer see pantoprazole litigation success
Forest / Merz settle memantine litigation
Astellas and Teva reach solifenacin patent litigation settlement
Rosuvastatin patent upheld in court
Teva sued by Bayer over oral contraceptive product
Barr withdraws thalidomide ANDA; Celgene dismisses lawsuit
Teva and AstraZeneca settle budesonide litigation
French Competition Authority to investigate alleged clopidogrel anti-competitive practices
Teva files oestrogens lawsuit against Watson; companies reach Seasonale settlement
Teva hit with US$356 million in punitive damages in Las Vegas trial
Shire receives further guanfacine Paragraph IV Notice letters; files lawsuit against Teva
Pozen enters sumatriptan / naproxen litigation settlement with Teva
Penwest and Endo settle oxymorphone patent litigation with Barr
Teva and Eli Lilly both see victory in gemcitabine ruling; Teva gains Seasonique ruling
sanofi-aventis enters series of oxaliplatin patent settlements
Teva enters temozolomide agreement
Teva sees losartan legal success
Teva announces settlement in principle in drug pricing lawsuits
Teva gains temozolomide success
Teva gains appellate lansoprazole victory
Teva reaches omeprazole, esomeprazole settlements with AstraZeneca
The Medicines Company files additional bivalirudin patent lawsuits
Trial date set for Cubist / Teva daptomycin case
Shire and Teva settle mixed amphetamines authorised generic litigation
Fentanyl buccal
Drospirenone / ethinyloestradiol (Yasmin)
Ethinyloestradiol / norgestimate (Ortho Tri-Cyclen Lo)

Skip to top

Ask Your Question

Teva Pharmaceutical Industries Generics Company Intelligence Report
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: